Sarepta Soars On New FDA Duchenne Drug Panel
This article was originally published in Scrip
Executive Summary
Investors took a much sunnier view on March 10 of Sarepta Therapeutics Inc. – driving its stock up as high as 16% – after the FDA announced a new date for its Peripheral and Central Nervous System (PCNS) Advisory Committee to examine the company's new drug application (NDA) for its experimental Duchenne muscular dystrophy (DMD) drug eteplirsen.